Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC dandruff monograph

This article was originally published in The Tan Sheet

Executive Summary

The final monograph for OTC dandruff, seborrheic dermatitis and psoriasis drug products is being amended to include the combination of 1.8% coal tar solution and 1.5% menthol in a shampoo drug product to control dandruff, FDA says in a March 6 Federal Register notice. The regulation is effective April 5, 2007. The agency solicited comments on the proposed amendment in late 2005, but did not receive any responses (1"The Tan Sheet" Dec. 12, 2005, p. 6)...

You may also be interested in...



FDA Proposes Coal Tar/Menthol Addition To OTC Dandruff Monograph

The final monograph for OTC dandruff, seborrheic dermatitis and psoriasis drug products would be amended to include a specific combination of coal tar and menthol under a proposed rule published by FDA in the Federal Register Dec. 9

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel